|
BIIB | Biogen Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.70 |
| Leverage | 37.66% |
| Market Cap | $ 25.8B |
| PE | 16.12 |
| Dividend Yield | 0.00% |
| Profit | $ 1.6B |
| Margin | 15.90% |
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.